Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
Adagene Inc. Sponsored ADR (ADAG) P/E ratio
Adagene Inc. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (April 2021) to 0.0× (April 2021) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| NBP NovaBridge Biosciences compare | n/m |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)